PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: MasterLink

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Nasal Flu Vaccines Provide 'Double' Immunity According to Carrington Laboratories - Carrington Laboratories, Inc. and DelSite Biotechnologies, an innovator in nasal vaccine delivery technology, have discovered that flu vaccines delivered nasally have shown to provide immunity both locally in the nasal passages and nasal mucosa [Nasdaq: C
Nasal Flu Vaccines Provide 'Double' Immunity According to Carrington Laboratories

 

NewswireToday - /newswire/ - Irving, TX, United States, 2007/02/17 - Carrington Laboratories, Inc. and DelSite Biotechnologies, an innovator in nasal vaccine delivery technology, have discovered that flu vaccines delivered nasally have shown to provide immunity both locally in the nasal passages and nasal mucosa [Nasdaq: C.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Carrington Laboratories, Inc.’s DelSite Biotechnologies subsidiary, an innovator in nasal vaccine delivery technology, said flu vaccines delivered nasally have been shown to provide immunity both locally in the nasal passages and also systemically as the vaccine penetrates the nasal mucosa.

"This feature of double immunity, and the speed with which the nasal passages become protected, can be very beneficial in immunizing children with immature immune systems and older people with weakened immune systems," notes Dr. Yawei Ni, senior scientist at DelSite Biotechnologies.

"The results reported today in The New England Journal Of Medicine on the enhanced efficacy of FluMist®'s, a live attenuated vaccine delivered as a liquid nasal spray, versus standard injected flu vaccines in children between the ages of six months and five years is a very encouraging note for the broader adoption of a nasal vaccine delivery option," he added.

DelSite's nasal powder vaccine delivery platform, called GelVac™, is a nasal powder vaccine delivery platform based on the GelSite® polymer technology. Having recently completed successful human safety Phase I study (with a GelSite® polymer powder system) and earlier preclinical work that established GelVac™’s ability to immunize subjects against severe flu challenges in a series of animal models, the vaccine delivery technology with antigen is scheduled to enter Phase I human testing. The company currently is in the process of acquiring flu antigen in order to initiate the human study.

About GelVac™
GelVac™, a nasal powder vaccine delivery platform, based on GelSite® polymer, is a dry powder formulation delivered nasally providing several potential advantages over other systems, including better stability, room temperature storage, no need for preservatives, no need for needles and is mucoadhesive providing prolonged nasal residence time. Nasal immunization induces both systemic and mucosal immune responses. The GelVac™ delivery system increases antigen nasal residence time, providing for prolonged contact with the mucosal surface which may improve immune response for many different classes of antigens.

About GelSite®
GelSite® polymer is a naturally sourced, high-molecular-weight anionic polysaccharide that exhibits distinct chemical and functional properties proprietary to the Company. GelSite® is water-based and is capable of in situ gelation, i.e., changing either a solid or liquid formulation into a gel upon contact with body fluids that leads to controlled-release of active biomolecules. GelSite® is not an adjuvant and is a member of a family of plant polysaccharides classified by the FDA as Generally Regarded As Safe (GRAS). The polymer is currently manufactured to cGMP standards at Carrington Laboratories wholly owned subsidiary, Sabila Industrial, SA.

About DelSite
Carrington's wholly-owned subsidiary DelSite Biotechnologies, Inc. is developing its proprietary GelSite® technology designed to provide controlled release of peptide and protein-based drugs. DelSite is currently developing a nasal powder vaccine using its GelVac? formula with the H5N1 avian flu antigen. This work is partially funded by two grants from the Department of Health and Human Services.

About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol® and cosmetic raw material Hydrapol™. Carrington also manufactures and distributes a complete line of wound care products for the professional veterinarian through its Veterinary Medical Divison (CarraVet™ Wound Care and the new EquineVet® Advanced Wound Therapy for horses). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. DelSite Biotechnologies, a subsidiary of Carrington, is developing its proprietary GelSite® technology designed to provide controlled release of peptide and protein-based drugs. A platform technology for a powder nasal delivery system is being developed for vaccine with emphasis and funding from the US HHS for the H5N1 (Bird Flu) Antigen. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world.

Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-Q, filed November 14, 2006.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: MasterLink

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Nasal Flu Vaccines Provide 'Double' Immunity According to Carrington Laboratories

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Doug Golwas - DelSite.com 
800-527-5216 info[.]carrington.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any MasterLink securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From MasterLink / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)